Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History

Pathogenic DNA variants associated with familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome are widely recognized as clinically important and actionable when identified, leading some clinicians to recommend population-wide genomic screening. To assess the...

Full description

Saved in:
Bibliographic Details
Published inJAMA network open Vol. 3; no. 4; p. e203959
Main Authors Patel, Aniruddh P, Wang, Minxian, Fahed, Akl C, Mason-Suares, Heather, Brockman, Deanna, Pelletier, Renee, Amr, Sami, Machini, Kalotina, Hawley, Megan, Witkowski, Leora, Koch, Christopher, Philippakis, Anthony, Cassa, Christopher A, Ellinor, Patrick T, Kathiresan, Sekar, Ng, Kenney, Lebo, Matthew, Khera, Amit V
Format Journal Article
LanguageEnglish
Published United States American Medical Association 01.04.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Pathogenic DNA variants associated with familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome are widely recognized as clinically important and actionable when identified, leading some clinicians to recommend population-wide genomic screening. To assess the prevalence and clinical importance of pathogenic or likely pathogenic variants associated with each of 3 genomic conditions (familial hypercholesterolemia, hereditary breast and ovarian cancer syndrome, and Lynch syndrome) within the context of contemporary clinical care. This cohort study used gene-sequencing data from 49 738 participants in the UK Biobank who were recruited from 22 sites across the UK between March 21, 2006, and October 1, 2010. Inpatient hospital data date back to 1977; cancer registry data, to 1957; and death registry data, to 2006. Statistical analysis was performed from July 22, 2019, to November 15, 2019. Pathogenic or likely pathogenic DNA variants classified by a clinical laboratory geneticist. Composite end point specific to each genomic condition based on atherosclerotic cardiovascular disease events for familial hypercholesterolemia, breast or ovarian cancer for hereditary breast and ovarian cancer syndrome, and colorectal or uterine cancer for Lynch syndrome. Among 49 738 participants (mean [SD] age, 57 [8] years; 27 144 female [55%]), 441 (0.9%) harbored a pathogenic or likely pathogenic variant associated with any of 3 genomic conditions, including 131 (0.3%) for familial hypercholesterolemia, 235 (0.5%) for hereditary breast and ovarian cancer syndrome, and 76 (0.2%) for Lynch syndrome. Presence of these variants was associated with increased risk of disease: for familial hypercholesterolemia, 28 of 131 carriers (21.4%) vs 4663 of 49 607 noncarriers (9.4%) developed atherosclerotic cardiovascular disease; for hereditary breast and ovarian cancer syndrome, 32 of 116 female carriers (27.6%) vs 2080 of 27 028 female noncarriers (7.7%) developed associated cancers; and for Lynch syndrome, 17 of 76 carriers (22.4%) vs 929 of 49 662 noncarriers (1.9%) developed colorectal or uterine cancer. The predicted probability of disease at age 75 years despite contemporary clinical care was 45.3% for carriers of familial hypercholesterolemia, 41.1% for hereditary breast and ovarian cancer syndrome, and 38.3% for Lynch syndrome. Across the 3 conditions, 39.7% (175 of 441) of the carriers reported a family history of disease vs 23.2% (34 517 of 148 772) of noncarriers. The findings suggest that approximately 1% of the middle-aged adult population in the UK Biobank harbored a pathogenic variant associated with any of 3 genomic conditions. These variants were associated with an increased risk of disease despite contemporary clinical care and were not reliably detected by family history.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Acquisition, analysis, or interpretation of data: Patel, Wang, Fahed, Mason-Suares, Brockman, Amr, Machini, Hawley, Witkowski, Koch, Cassa, Ng, Lebo, Khera.
Critical revision of the manuscript for important intellectual content: All authors.
We thank the UK Biobank and its participants who provided biological samples and data for this analysis.
Concept and design: Patel, Fahed, Pelletier, Philippakis, Ellinor, Kathiresan, Khera.
Statistical analysis: Patel, Wang, Fahed, Khera.
Additional Contributions
Obtained funding: Patel, Philippakis, Cassa, Ng, Khera.
Administrative, technical, or material support: Mason-Suares, Pelletier, Cassa, Ellinor, Lebo.
Supervision: Ellinor, Lebo, Khera.
Author Contributions
Drafting of the manuscript: Patel, Fahed, Khera.
Drs Patel and Khera had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Patel and Wang contributed equally to this study.
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2020.3959